Two in Three People With Alzheimer's Are Women. What the Research Actually Supports. | APEX PWR Tigard & Beaverton

APEX PWR  |  Lessons in Longevity & Female Fitness

Two in Three People With Alzheimer's Are Women. Here Is What the Research Actually Supports.

By The APEX Team  |  Tigard & Beaverton, Oregon  |  November 18, 2026

Key Takeaways

  • Almost two thirds of Americans living with Alzheimer's are women. Of the 7.4 million people aged 65 and older with the disease, 4.5 million are women.
  • Longer life expectancy is the long-standing explanation, and researchers are now questioning whether it is the whole story. The Alzheimer's Association says so in plain terms.
  • Brain imaging through the menopause transition shows real measured differences in how the brain uses glucose, in a small but careful study of 43 women aged 40 to 60.
  • The claim going around that hormone therapy cuts Alzheimer's risk by up to 50% overstates its source. The study it points at reported a 15% to 26% reduction in deaths from dementia, which is a different outcome.
  • Randomized trials in women aged 65 and older found the opposite direction, with higher dementia risk on hormone therapy. Timing and formulation appear to matter and the midlife trial has never been run.
  • Twice weekly resistance training improved attention and memory in a six month randomized trial of 86 women aged 70 to 80. Small study, real design, and the only lever here that needs no prescription.

A carousel has been going around this month with a number on the front of it. Two out of every three Alzheimer's patients in the United States is a woman. That is followed by a confident explanation, a confident solution, and a confident instruction about what every woman should be doing at 45.

The number on the front is right. We went and read the studies behind the rest of it, and some of what follows that first slide does not hold up the way it is presented.

We are writing this anyway, because the underlying question is a good one and the women in our building keep asking it. Our goal here is to separate what the research supports from what it is being made to say.

The Gap Is Real

The Alzheimer's Association states it directly: almost two thirds of Americans living with Alzheimer's are women. Of the 7.4 million people aged 65 and older with the disease in this country, 4.5 million are women.

4.5M
women aged 65 and older living with Alzheimer's in the United States, out of 7.4 million people
Alzheimer's Association
~2 in 3
of Americans living with Alzheimer's are women
Alzheimer's Association
Up to 45%
of dementia cases worldwide that could in theory be prevented or delayed by addressing 14 modifiable risk factors
Lancet standing Commission, 2024

Now the part the carousel skips. The Alzheimer's Association also writes that the prevailing view has been that this difference comes down to women living longer on average, and that age is the greatest risk factor for the disease. It then says researchers are now questioning whether risk could be higher for women at any given age.

Read that carefully, because the framing matters. Longevity is the established explanation. Whether something beyond longevity is also at work is an open research question that serious people are actively investigating. The carousel asserts that longevity has been ruled out. It has not been.

A question that researchers are still working on is a reason to pay attention. It is not yet a finding you can act on as though it were settled.

What the Brain Imaging Actually Shows

There is real science underneath the hormone part of this, and it deserves better than a slide.

Estrogen receptors are present throughout the brain, including regions involved in memory. Estrogen is involved in how brain cells take up and use glucose, which is their primary fuel. That is established biology, not a claim.

The study people are referring to when they post those two side-by-side PET scans was led by Lisa Mosconi at Weill Cornell Medicine with Roberta Brinton at the University of Arizona, published in PLoS One in 2017. The researchers scanned 43 healthy women aged 40 to 60, split into 15 premenopausal, 14 perimenopausal and 14 postmenopausal. The perimenopausal and postmenopausal groups showed lower brain glucose metabolism in several regions than the premenopausal group, along with lower activity of a key mitochondrial enzyme and lower scores on standard memory tests.

That is a careful piece of work and it is genuinely interesting. Two honest caveats come with it.

The first is sample size. Forty three women, in three groups of roughly fourteen. That is enough to generate a hypothesis worth chasing and it is not enough to settle anything.

The second is the figure being quoted. The widely shared version says brain glucose uptake drops "up to 30% within 5 years." The 30 percent figure traces to an image caption describing one illustrative scan comparison, rather than to a reported study result across the group, and the study was cross-sectional, meaning it compared different women at different stages rather than following the same women across five years. We would rather you had that from us than find it out later.

The 50% Claim, and What the Study Said Instead

This is the part we most wanted to check, because it is the part that would change what a woman does.

The carousel cites Manson 2017 and Manson 2020 and states that hormone therapy started within ten years of menopause reduces Alzheimer's risk by up to 50 percent.

Here is what the 2017 paper in JAMA reported. It was the long-term follow-up of the Women's Health Initiative, the largest randomized hormone therapy trial ever conducted, covering 18 years. For deaths from Alzheimer's disease and dementia, it found:

Trial armHazard ratio for dementia mortalityIn plain terms
Pooled trials0.85 (95% CI 0.74 to 0.98)About 15% fewer deaths from dementia
Estrogen alone0.74 (95% CI 0.59 to 0.94)About 26% fewer deaths from dementia
Estrogen plus progestin0.93 (95% CI 0.77 to 1.11)No statistically significant difference

Two things are off in the viral version. The size, where 26 percent in the best arm has become 50. And the outcome, because the trial measured deaths from dementia rather than whether a woman went on to develop the disease. Those are different questions, and treating one as the other is how a modest finding becomes a headline.

There is a second body of evidence that the carousel leaves out entirely. A 2023 systematic review and meta-analysis pooled the randomized trials of hormone therapy and dementia and found that in women aged 65 and older, hormone therapy was associated with a higher dementia risk, with a relative risk of 1.38. The combined estrogen and progestogen trials drove that result.

The same review found that observational studies of women who started in midlife pointed the other way, with roughly a 32 percent lower dementia risk for estrogen-only therapy. Observational studies cannot rule out that the women who choose hormone therapy in midlife differ in other ways from the women who do not.

Where This Leaves It

Started late, randomized trials show harm. Started in midlife, observational data suggest benefit. The randomized trial of midlife initiation has never been run, which is exactly why the confident version is wrong in both directions.

What We Are Not Going to Do

We are not going to tell you whether to take hormone therapy. We do not prescribe it, and a decision with real benefits and real risks on both sides belongs with you and a clinician who knows your history, your family history and your own risk profile.

What we will say is that the timing question is worth raising with that clinician in your forties rather than waiting until something feels wrong. If you want a practitioner who takes menopause seriously, that is a reasonable thing to go looking for, and a clinician certified by The Menopause Society is a sensible place to start.

The carousel is right about one thing without qualification. These conversations happen too late and too briefly, and women are often sent away from them with less than they came in with.

The Lever We Can Actually Put Our Hands On

Here is the finding we think deserved the front slide.

In 2012, a research team published a six-month randomized controlled trial in Archives of Internal Medicine. Eighty six community-dwelling women aged 70 to 80, all with probable mild cognitive impairment, were randomized into three groups training twice a week: resistance training, aerobic training, or a balance and tone control.

The resistance training group showed significant improvement in selective attention and conflict resolution on the Stroop test, and significant improvement in associative memory, compared with the control group. Functional MRI in a subset showed changes in brain activity during the memory task, and the degree of change in one region tracked with the degree of memory improvement. The aerobic group improved balance, mobility and cardiovascular capacity, and did not show the same cognitive changes on these particular measures.

86
women aged 70 to 80 with probable mild cognitive impairment, randomized
Nagamatsu et al., Arch Intern Med 2012
2×/week
resistance training, 60 minute sessions, over six months
Nagamatsu et al., Arch Intern Med 2012
6 months
to measurable improvement in attention and associative memory versus the control group
Nagamatsu et al., Arch Intern Med 2012

We will hold this one to the same standard we held the others to. The sample was small. The participants already had mild cognitive impairment, so this is a study about improving function in people who had begun to lose some, rather than a trial showing that lifting prevents dementia. Adherence was imperfect, which the authors note themselves. The findings may not generalize to men or to younger women.

With all of that said, it is a randomized controlled trial, in women, on resistance training specifically, with a measured cognitive outcome and brain imaging to go with it. That is a stronger piece of evidence than most of what gets posted about women's brain health, and it is the one nobody is making a carousel about.

Resistance training also happens to be the intervention with the best evidence for the other things that change through the menopause transition: muscle mass, bone density, insulin sensitivity and strength. The brain findings are a bonus on top of a list that already justified it.

What We Would Actually Suggest for a Woman in Her Forties

Nothing here is a protocol and none of it requires you to believe anything contested.

Lift, at least twice a week

Progressive resistance training, heavy enough that the last few repetitions are genuinely hard, coached if you have not done it before. Twice a week is the dose in the trial above. Three is better for the muscle and bone side. If you have never trained, the first six weeks are about learning the movements rather than chasing numbers, which is what our strength training for women through perimenopause is built around.

Get a baseline you can compare against later

A DEXA body composition scan tells you your lean mass and where your fat sits. A bone density scan tells you where your skeleton is, and the thirties and forties are when that trend is still changeable. One reading places you. Two readings, a year or two apart, show your direction, and the direction is the part that changes decisions.

Treat the boring risk factors as the main event

The 2024 Lancet standing Commission on dementia identified 14 modifiable risk factors across the life course and estimated that addressing all of them could in theory prevent or delay up to 45 percent of dementia cases worldwide. Blood pressure. Hearing. Physical inactivity. Smoking. Obesity. Diabetes. Alcohol. Depression. Social isolation. Air pollution. Head injury. High LDL cholesterol. Less education. Untreated vision loss.

That is a population-level estimate and not a personal guarantee. It is also a list with almost nothing exotic on it, and it is a long way from a six-item lab panel that nobody will run for you.

Have the conversation with a clinician who knows the area

Bring your family history. Ask about the timing question. Ask what your own numbers look like. Our wellness team can point you toward people locally who work in this space, and our physical therapy and wellness team works alongside physicians regularly.

Coming in January

We are hosting a women's health and strength workshop at APEX in early January 2027 with Dr. Elizabeth Wade, a naturopathic doctor in Portland. She covers hormones, metabolism, blood sugar and energy. Our coaching team then runs a hands-on strength session built for women who are new to lifting or want to fix their technique.

Details are being finalized. Reply to our newsletter or email the team to get on the interest list.

You Do Not Have to Wait for January

Coached strength training for women in Tigard, Oregon, minutes from Beaverton. Group or one to one, with DEXA scanning and nutrition support in the same building.

Strength Training Foundations Trial Personal Training Foundations Trial

Frequently Asked Questions

Why are most people with Alzheimer's women?
The Alzheimer's Association reports that almost two thirds of Americans living with Alzheimer's are women, and that 4.5 million of the 7.4 million people aged 65 and older with the disease are women. The long-standing explanation is that women live longer on average and age is the largest single risk factor. The Association also states that researchers are now questioning whether women's risk may be higher at any given age, which remains an open question rather than a settled finding.
Does menopause cause Alzheimer's disease?
No study has shown that it does. Imaging research by Mosconi and colleagues in 2017 compared 43 healthy women aged 40 to 60 and found lower brain glucose metabolism and lower mitochondrial enzyme activity in perimenopausal and postmenopausal women than in premenopausal women. That is a measured difference in a small cross-sectional sample. It is a reason to take the question seriously and it is not evidence of cause.
Does hormone therapy reduce Alzheimer's risk by 50 percent?
No published trial supports that figure. The Manson 2017 analysis of the Women's Health Initiative reported deaths from Alzheimer's and dementia over 18 years, with hazard ratios of 0.85 pooled and 0.74 in the estrogen-alone arm, which are reductions of roughly 15 and 26 percent on a mortality outcome. A 2023 systematic review found that in randomized trials of women aged 65 and older, hormone therapy was associated with higher dementia risk, relative risk 1.38. Timing and formulation appear to matter, no randomized trial has tested midlife initiation, and this is a decision for you and a qualified clinician. APEX PWR does not prescribe hormone therapy.
Can strength training help brain health in women?
There is randomized evidence worth knowing about. In a six-month trial published in 2012, 86 community-dwelling women aged 70 to 80 with probable mild cognitive impairment were randomized to twice-weekly resistance training, aerobic training, or a balance and tone control. The resistance training group significantly improved on selective attention and associative memory compared with control, with accompanying changes on functional MRI. The sample was small and participants already had cognitive impairment, so it falls short of proving that lifting prevents dementia. What it does give you is the strongest signal available for a lever entirely within your control.
I am 45 and have noticed brain fog. Should I be worried?
Cognitive changes during the menopause transition are commonly reported and are usually not an early sign of dementia. Sleep disruption, hot flashes, stress and mood all affect memory and concentration on their own. That said, anything new and persistent is worth raising with your physician rather than reading about online, and that is true whatever the cause turns out to be.
Is it too late if I am already postmenopausal?
The resistance training trial described above was run in women aged 70 to 80 who already had mild cognitive impairment, and it still found improvement over six months. On the strength, muscle and bone side, every age group studied has responded to progressive resistance training. The timing argument applies to the hormone question specifically, and it does not apply to training.
Serving: TigardBeavertonPortlandLake OswegoTualatinKing CitySherwoodHillsboro
This article is educational and is not medical advice, a diagnosis, or a substitute for care from your own physician. APEX PWR does not prescribe or manage hormone therapy. Decisions about menopausal hormone therapy involve benefits and risks that differ by age, time since menopause, formulation and personal and family medical history, and belong with you and a qualified clinician. Several of the studies described here report associations observed in population cohorts or findings from small samples, neither of which establishes cause. No training program can be promised to prevent dementia, Alzheimer's disease or cognitive decline. If you have noticed new or persistent changes in memory, attention or mood, speak with your physician.
Sources. Alzheimer's Association, Women and Alzheimer's: almost two thirds of Americans living with Alzheimer's are women; of the 7.4 million people aged 65 and older with Alzheimer's in the United States, 4.5 million are women; the Association describes longer female life expectancy as the prevailing explanation and states that researchers are now questioning whether risk is higher for women at any given age. Mosconi L, Berti V, Quinn C, et al. Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. PLoS One, 2017; 43 healthy women aged 40 to 60 (15 premenopausal, 14 perimenopausal, 14 postmenopausal); lower brain glucose metabolism and lower mitochondrial cytochrome oxidase activity in peri- and postmenopausal groups; cross-sectional design. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017; cumulative 18-year follow-up; Alzheimer's disease and dementia mortality pooled HR 0.85 (95% CI 0.74 to 0.98), conjugated equine estrogen alone HR 0.74 (95% CI 0.59 to 0.94), conjugated equine estrogen plus medroxyprogesterone acetate HR 0.93 (95% CI 0.77 to 1.11). Nerattini M, Jett S, Andy C, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia, 2023; randomized trials in women aged 65 and older, hormone therapy RR 1.38 (95% CI 1.16 to 1.64); midlife estrogen-only observational RR 0.685 (95% CI 0.513 to 0.915). Nagamatsu LS, Handy TC, Hsu CL, Voss M, Liu-Ambrose T. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Archives of Internal Medicine, 2012; 172(8):666-668; 86 community-dwelling women aged 70 to 80, six months, twice weekly; resistance training improved Stroop performance (p = 0.04) and associative memory (p = 0.03) versus balance and tone control. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission; 14 modifiable risk factors, up to 45 percent of dementia cases potentially preventable or delayable worldwide.

Previous Blogs

What a Real Travel Nutrition Plan Looks Like

What a Real Travel Nutrition Plan Looks Like | APEX PWR Tigard & Beaverton APEX PWR  |  Nutrition Nook What a Real Travel Nutrition Plan Looks Like By The APEX Team  |  Featuring Jennie Carolan, MS  |  Tigard & Beaverton, Oregon  |  November 4, 2026 Key Takeaways A client told his coach he was headed

Read More »

When Should a Woman Get Her First Bone Density Scan?

When Should a Woman Get Her First Bone Density Scan? | APEX PWR Tigard & Beaverton APEX PWR  |  Female Fitness When Should a Woman Get Her First Bone Density Scan? By The APEX Team  |  Tigard & Beaverton, Oregon  |  November 4, 2026 Key Takeaways The headline number is 65. US screening guidelines recommend

Read More »
Scroll to Top

Learn the 7 PWR Moves to
Get More Out of Life

7 Proven PWR Moves to help you silence the noise, and streamline success in your health & fitness.

  • This field is for validation purposes and should be left unchanged.